Financials
Financial year 2025
PHARMAPLUS INVEST from Vorst, company number BE0505864007, closed financial year 2025 with a result of € 59,853 after tax. For that financial year PHARMAPLUS INVEST recorded a gross margin of € 274,101 and equity of € 72,734. Compared with financial year 2024, the result moved from € 87,055 to € 59,853. The company is profitable. The buffer shrank hard: equity is 55 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 21, 2026.
€ 72,734
▼ 55% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 59,853
▼ 31% vs 2024
Profit after tax over the fiscal year.
€ 528,512
▲ 3% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 150,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
1.6
▲ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 73,055
▲ 24% vs 2024
€ 45,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 27,055
▼ 24% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 217,150
▼ 18% vs 2024
€ 56,324 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 69,329
▲ 32% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 16,482
▲ 42% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 246,058 | € 257,876 | € 269,261 | € 274,101 | ▲ 2% |
| Profit after taxes | € 95,718 | € 93,866 | € 87,055 | € 59,853 | ▼ 31% |
| Equity | € 181,960 | € 175,826 | € 162,881 | € 72,734 | ▼ 55% |
| Total debts | € 805,929 | € 801,313 | € 844,576 | € 903,273 | ▲ 7% |
| Cash | € 406,524 | € 467,117 | € 515,234 | € 528,512 | ▲ 3% |
| Retained profit | € 151,960 | € 145,826 | € 132,881 | € 42,734 | ▼ 68% |
| Dividend | € 100,000 | € 100,000 | € 100,000 | € 150,000 | ▲ 50% |
| Bank debt | € 362,363 | € 317,900 | € 263,378 | € 217,150 | ▼ 18% |
| Balance sheet total | € 987,889 | € 977,140 | € 1,007,458 | € 976,007 | ▼ 3% |
| Employees (FTE) | 1.2 | 1.4 | 1.5 | 1.6 | ▲ 0.1 |
Key figures of PHARMAPLUS INVEST, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMAPLUS INVEST?
What happened at PHARMAPLUS INVEST in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 59,853 (▼ 31% vs 2024). filed late Source: NBB ↗
- New establishment in Vorst. KBO
- Start of the company according to the CBE. KBO
- KATTY MOSZYNSKI became a director. NBB
In short
From € 95,718 profit in 2022 to € 59,853 profit in 2025.
Paid € 164,688 in corporate taxes since 2022.
Best year ever: 2022, with € 95,718 profit.
On average € 171,300 of value added per employee in 2025.
A new publication or filing at PHARMAPLUS INVEST? We notify you, reason included.
Follow PHARMAPLUS INVESTDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMAPLUS INVEST is KATTY MOSZYNSKI.
Directors
According to the 2025 annual accounts
KATTY MOSZYNSKI
Manager
since 2014
Establishments
Establishment units
Physical locations of this company
Neptunuslaan 34
1190 Vorst
Neptunuslaan 45 box 4
1190 Vorst
Active since 25 November 2015
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0505.864.007
- VAT number
- BE 0505.864.007
- Registered office
- Neptunuslaan 34, 1190 Vorst
- Names & denominations
- PHARMAPLUS INVEST
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 2 December 2014
- Peppol
- Active · Active since 7 Mar 2025
- Activities · NACE
Detailhandel in farmaceutische producten